#USA #Minneapolis #financial results #Bio-Techne #Fiscal 2026

Bio-Techne Corporation's Q2 Fiscal 2026 Results

Bio-Techne Corporation has released its financial results for the second quarter ended December 31, 2025. The company reported stabilizing growth figures, maintaining its position in the industry as it adapts to various market conditions.

Financial Highlights

In the second quarter, Bio-Techne generated revenues of $295.9 million, reflecting consistent performance compared to the previous year. Despite facing challenges, both reported and organic growth remained flat year-over-year. The company's GAAP earnings per share (EPS) rose to $0.24, an increase from $0.22 a year prior. Furthermore, adjusted EPS also climbed, hitting $0.46 from last year's $0.42.

Management attributes the stability to ongoing productivity improvements and cost containment strategies, which resulted in an astonishing 31.1% adjusted operating margin, marking a 100 basis point increase from the prior year. This resilience in performance was further emphasized by the growth of the company's commercial operations in the China and APAC region for the third consecutive quarter.

CEO Kim Kelderman expressed satisfaction with the firm's performance, noting the team's ability to execute effectively in a stabilizing operational environment. He pointed out that the company achieved double-digit growth in its primary market, large pharmaceuticals, for four consecutive quarters, a feat that has fueled optimism about future business prospects.

Detailed Financials

Delving deeper into the financial results, the company reported that its Protein Sciences segment continues to be a leading supplier of specialized proteins, contributing $215.1 million in net sales, up 2% from $211.6 million in the previous fiscal quarter. Despite the small increase in sales, organic revenue saw a 1% decline.

On the other hand, the Diagnostics and Spatial Biology segment saw a drop in sales of $81.2 million, down 4%, but organic revenue growth was reported at 3%, aided by favorable foreign exchange impacts. The segment’s efficiency improved, as seen in its operating margin climbing to 10.4% from 3.9% during the same time last year.

Future Outlook

As Bio-Techne approaches its 50th anniversary in 2026, the leadership of the organization remains optimistic about its path forward. With a resilient product portfolio catering to high-demand markets, the company aims to continue driving innovation, growth, and value for its stakeholders.

The company's success in maintaining strong revenue and margins amidst external pressures reflects its strategic focus on high-growth opportunities, thereby reinforcing its market position within the life sciences sector.

Earnings Conference Call

To discuss these results further, Bio-Techne is hosting an earnings conference call on February 4, 2026, at 8:00 a.m. CST. Interested parties can join by calling 1-800-579-2543 (U.S.) or 1-785-424-1789 (international) and referencing conference ID TECHQ2. The call will also be accessible via a webcast on the company’s investor relations website.

Conclusion

Bio-Techne Corporation's latest financial results indicate a stable performance against a backdrop of fluctuating market conditions. The proactive measures taken to ensure productivity and cost efficiency exemplify the company's commitment to maintaining strong financial health as it continues to innovate and lead in the science and medicine field.

As the company celebrates a landmark anniversary, expectations are on the rise for its future endeavors and growth trajectories, especially in the ever-evolving life sciences arena.